Healthcare News 10

• "FDA Panel Votes Against New Avastin Use": The other shoe falls!!!
• "High quality" care and communication with patients will be rewarded- When Pigs Fly....
• "ME TOO" says Imclone's ( and Merck & BMS) Erbitux.....
• "Second Star on the Right...Straight on 'Til Morning": The Blues Journey to "Neverland"
• "Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture" Yea!! It appears to!!!
• 4SC pyrimadine-acting agent in RA: too little info, too soon to interpret!
• a better methotrexate?
• A cautionary note.
• A different way of addressing constipation
• A good nasal steriod
• A Holy Grail For Aging Eyes
• A market expansion for a very good product
• A new and significant drug for acute heart failure is now available in Canada
• A new antimuscarinic
• A new era in Parkinson's Disease treatment?
• A new venture from Akorn, Inc.- FDA approval for a unit dose preservative free Tetanus Diphtheria vaccine
• A new way to protect our patients from one of the complications of corticosteroids
• A novel approach to an old disease
• A possible step forward for patients with brain tumor
• A potentially welcome addition to managing a difficult problem, but response rate is not overwhelming
• A Real Stretch
• A small niche in the PPI market
• A smart strategic move--how to maximize corporate benefit from a molecule
• A strange study
• A viable alternative to IVIG
• A welcome reality check
• Abbott's Humira: a key step towards market leadership in psoriasis
• Ablynx may have a benign antibody for 2 "malignant" conditions
• Addition of meningococcal vaccine for younger children won't add much value
• Agomelatine, An Antidepressant Without Weight Gain and Sexual Side Effects?
• Almirall's new drug aclidinium bromide (LAMA class for COPD) will add to COPD market in substantive way
• Alogliptin on the diabetes horizon.
• AMAG poised to capture large segment of IV iron market and grow market share in CKD
• Ambrisentan (Letairis) gaining ground against Tracleer
• American Academy of Ophthalmology Issues Press Statement Criticizing Genentech's Decision to Limit Avastin Availability for the Treatment of Wet Macular Degeneration
• Amgen is fighting a losing battle against a fair Medicare decision
• Amgen, Who are they advocating for???
• Amgen: use an act to upstage science!
• An anti TNF that appears to work
• An idea whose time has come?
• An important extension of protection
• An Update on Doctor Ranking Systems
• analysis
• Analysis of AMP Injunction
• Analysis of CRx-191 in Psoriasis - Comments
• Anesiva works in minutes as topical anesthetic for IV access
• Another case of big pharma not realizing the real issue
• Another Medicare Health Support Project is Canceled Early.
• Another nail in its coffin
• Another nail in the coffin
• Another Nail in the Coffin
• Another piece of good news for a very good drug
• Another player in MM treatment?
• Another SERM-any better than what we already have?
• Another weapon in the armamentariun for treating this difficult condition
• Approval in India means little in U.S.
• As ZymoGenetics, Ethicon, King Gird for Thrombin Battle, Baxter Gets FDA Nod for Its Convenient Thrombin/GELFOAM Kit
• Asentar(TM) (DN-101,Novacea) Phase III Trial Terminated for Safety concerns??
• ASH says it and that is the final word on Epo use? (Maybe)
• AstraZeneca Initiates a Gutsy Study, Head to Head Against Tarceva in Lung Cancer!!
• AstraZeneca’s Seroquel XR: Acute….Maintenance…What’s next?!
• ASTRO 2007: Rapid Arc Efficient, Expensive or both?
• Asuragen & Merck: Trend Setters with Pharmacogenomic Testing
• Asuragen given contract to develop oncology biomarker assay for Merck
• Atripla - A welcome addition to EUropean antiretroviral regimens
• Avandia is going down the drain
• Avastin - hope for brain tumor patients?
• Avastin Approval for Renal Cell Carcinoma: Better than Sutent?
• Avastin Approved in Europe for Renal Cell Carcinoma- Is it Better than Sutent?
• Avastin approved in kidney cancer (RCC) in Europe! Good for Roche but for the patients......
• Avastin for Glioblastomas (GBM)- It's Time Has Come?
• Avastin in breast cancer
• Avastin In breast cancer overdue
• Avastin in Breast Cancer: Is the smoke clearing??
• Avastin in Kidney Cancer? Yes but.....
• Avastin in metastatic breast cancer? I told you so.
• Avastin in renal cell carcinoma: role is in comination with oral agents
• Avastin is effective in the first line setting of metastatic breast cancer!
• Avastin receives positive recommendation from the European Committee for Medicinal Products for Human Use (CHMP)
• Avastin: a promising agent for the treatment of the most aggressive brain tumour. By Dr. Xin Mao
• AVAX HNP modified tumor vaccine to undergo Phase III testing in metastatic melanoma
• Avax Phase III Trial: Headed in the right direction.....
• Bad news
• Baraclude the industry leader, new long term data
• Bausch & Lomb Currently Faces 573 Product Liability Lawsuits Stemming From Eye Infections Caused by ReNu MoisturLoc Contact Lens Solution
• Bayer's Blood-Sparing Drug Trasylol Is Now in Critical Condition
• Beating Breast Cancer: Bristol-Myers Squibb Co on top
• BEEF OR BULL? CHAPTER 7 for TOPPS MEAT Co. after RECALL of 11,000 TONS of BEEF linked to E. Coli.
• Begining of the end for Western vaccine manufacture
• Behind the Scenes of Pfizer UK's Distribution Plan
• Benchmarking Gone Amok
• Bendamustine (Treanda; Cephalon Inc, Frazer, PA) Just when you thought there were no new chemotherapeutic agents.....
• Better BP control is not the only issue.
• Betting on bone density and not osteosarcoma
• Bexxar & Zevalin Reimbursement Cuts by Medicare? Not a good Idea
• Big 3 Wholesalers Ramp Up Sourcing from India
• Biostatistics: Subgroup Analysis in Clinical Trials
• Biotech/Biological Alternative for the same chemicals
• Bipolar Disorder in the 10-17 Year Old Market
• Bite (Micromet). Is it's bark worse than it's......
• BITE Antibodies: Potential Immunotherapy for hematological malignancies
• Boceprevir
• Bone substitute
• Breast cancer therapy being effected by false + or - "targeting" results
• Breast Cancer, Lung cancer Cancer of the...... Pharmacogenomics should control our choices
• But What Does it Mean for The Patient in the Real Clinical Arena?
• Campath- usage in CLL will increase? Not so fast.....
• Can this New Technology Eliminate the Risk of Retained Surgical Sponges?
• Can you be both right and wrong?
• Capecitabine/Tarceva in Pancreatic Ca?
• Cardiac problems with sutent
• Cardinal Diversion Comments concerning DEA Suspension
• Cardinal Health's Diversion Problem Gets Worse
• Cardinal Still Has a Diversion Problem
• Cardiovascular risks no laughing matter
• Celgene buying Pharmion? Synergy??!!
• Centecor Ustekinumab- an impressive product for psoriasis
• Centocors Ustekinumab in psoriasis
• Chlamydia Rapid Test
• Chondrogen addresses post-surgery indication, NOT specifically OA treatment
• Chronic Hepatitis C therapy huge target:new monotherapy role pre-mature
• Cimzia in Crohns Disease
• Clinical data not surprising, cost data may be misleading...The question is when to use Remicade and in whom.
• CMS Should Require Medicare Cost Reports from Ambulatory Surgery Centers
• COMBIGAN (AGN) will not add much to the Lucrative Glaucoma Market.
• Combination therapy for COPD is a good idea
• Combination therapy with PegIFN and ribavirin showed better SVR
• CombinatoRx in psoriasis
• Combined drug effects to reduce obesity- results from Amylin Pharmaceuticals, Inc.
• Competition for Lantus
• Components of the medication studied have been tried for weight loss already! Phentermine
• Conformation of previous concerns
• Consider host-risk issue witth Remicade first!
• Convenience or Innovation?
• Cost is key, but not enough!
• Cost is the most critical factor in patient's decision to use Botox and soon Reloxin
• cost vs quality
• Cover all the uninsured without spending a penny
• CRx-191 - an intriguing combination product
• Cut in reimbursement vs. upfront costs....
• CVS/Caremark vs. Walgreens Lawsuit Highlights Pharmacy Challenge
• Cymbalta (Eli Lilly: LLY) Gets FDA Seal of Approval for Long-term Depression Management
• Cytos melanoma vaccine shows promising immuno-responses but has long way to go
• DDAVP : New warnings will impact use in Nocturnal Enuresis
• DDAVP can causes water intoxication - which can be very serious.
• Decline in Tracleer sales - how does it affect Swiss biotech company Actelion Ltd ?
• Decoys and red-herrings
• delayed release oral suspension for Protonix
• Delivery of nerve growth factor to the brain is in infant stage of research
• Depression as Mortality Risk in Diabetes
• Desmopressin Clinical use
• Desmopressin indications quite curtailed
• Development to treat Parkinson's disease - a new agent- Lu AA47070
• DexCom Makes Progress Towards Easier Glucose Monitoring
• Different Spin On Same Story
• Do Dynavax's vaccine adjuvants cause Lupus!
• Doctor Ranking Systems are Inevitable
• Does The FDA Acceptance of The NDA for Asenapine Signal A Good Outlook for Schering-Plough (NYSE: SGP)?
• Does this difference matter?
• Double edged sword
• Double or nothing: the host decides!
• Dow Chemical Co. Moves to Strengthen its Financial Fortress by Streamlining Workforce
• Drugs and Reversible Biologic Antithrombotics
• Dynavax's lupus program
• Efficacy and tolerability?
• Eisai to delay the regulatory submission of E2007- a prospective agent to treat Parkinson's disease
• Enlarging the indicated age range may not be a completely beneficial thing
• EPA for cardiovascular program
• EPIX Pharmaceuticals’ PRX-03140 Demonstrates Short-Term Pro-cognitive Effects In Patients With Alzheimer’s Disease, Longer Studies Are Needed To Evaluate It’s Potential Disease Modifying Effects.
• Erbitux in Lung cancer: new competitor for Avastin?
• Erbitux in first line therapy for lung cancer: The result is as thrilling as kissing your sister....
• Erbitux is consolidating its position in treatment of advanced colrectal cancer
• Erbitux On a Roll
• Erbitux, an alternative to Avastin in SOME metastatic colorectal carcinoma patients.
• Erlotinib Effect in Gemcitabine-Refractory Advanced Pancreatic Cancer
• Even more benefit.
• EXCELLENT NEWS: Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc
• Exelixis XL-184 c-MET and VEGFR2 inhibitor
• FCC Puts its Money Where its Mouth is to Help Finance the National Health Information Network
• FDA approval, if obtained, for use of Lexapro in adolescents will matter to Lexapro/Forest
• FDA Embraces Need to Better Inform Physicians
• Fewer pills is clearly better, but-
• First of many topical NSAIDs can revolutionize safer treatment of common Osteoarthritis!
• For some drugs it matters, for others less so
• Forest (FRX) Seeks Expansion for Lexapro into Adolescent Market
• Forodesine HCL in cutaneous lymphoma
• Forteo increases bone but does it decrease fracture risk
• Fortifying with Forteo
• Fosrenol - potentially another phosphorus binder option for stage 3/4 CKD
• Frivolous patent chanlleges: is there a reasonable solution?
• Further issues?
• Future Eloxatin Killer?
• Future of healthcare in middle east
• Galpagos & Lilly collaboration: osteoporosis
• Galvus is rpbably cooked
• GBM: Crowded field of potential drugs, but NO real winner!!!
• Genentech enrages vitreoretinal specialists
• Generic Drugs are not the same as Branded (Ethical) drugs, and sometimes it does not matter other times it may.
• GENETECH BACKTRACKS ON ITS DECISION TO LIMIT AVASTIN FOR WET MACULAR DEGERNATION
• Genetic Testing
• Geron receives $4,000,000 from Merck: A drop in the bucket?
• GlaxoSmithKline appears inches away from approval of CERVARIX®.
• Going bananas over peanuts
• Good idea
• Good news for treating advanced PD
• GPC Biotech AG cuts staff nearly in half and holds cash signal of weakness.
• Great concept but with a caveat
• Great concept if can deliver the right dose needed
• Great if it works
• Great News For Seroquel XR
• Great potential for S1
• GSK has a potential winner!!
• HD Supply Begins to Un-Rollup
• HeptoVax Trial Not Interpretable Yet
• Hits Allergan and grows the market
• HIV vaccines a possibility?
• HOLD ON TO YOUR WALLETS BABY BOOMERS. Looking through a prism darkly.
• Hope for TS-032 (a new schizophrenia drug) in the global market: joint venture by Taisho and Pfizer
• Hope from China?
• Hospice and the Skilled Nursing Home Patient
• Hospitals Respond to the Latest Government "Rob Peter to Pay Paul" Scheme
• I don't BiTE
• If Rikelta Works Better Than Other Epilepsy Agents, it Will Probably be Due to its Improved Toxicity Profile
• If we view business interest as an indicator of efficacy glutamate-based treatment of schizophrenia is a success
• IL-21 More Biologic Fodder for Melanoma
• I'll believe it when I see it
• Imcyte's JAK 2 Inhibitor (INCB18424). I see a window in Myelofibrosis!!
• Immune enhancement
• Impact may not be great
• Implications of natricor availability on perioperative low cardiac output
• Important data in a difficult to treat subpopulation
• Incyte may have a winner in a disease that has previously been difficult to treat.
• India - moving up the value chain
• Injection regimen for IAHA products
• Innovation is not the Issue: The Question is, Does Aprotinin Improve Outcomes?
• Innovative technology of uncertain usefulness
• In-office diagnosis is nice, but....
• Integriin and bivalirudin inhibit platlets better (so what)l
• Interesting, but not ready for prime time
• Interleukin-21 Phase 2 Clinical Trial in Advanced Melanoma Set to Begin
• Intriguing, but not really relevant
• IPI-504: Potential Activity But Limited Data
• IPI-504: another targeting agent for another target.
• Irony in Drug Therapy
• Is Potential Taisho-Pfizer Alliance on mGluR Schizophrenia Drug Candidate Coming Too Late?
• Is pramiconazole a breakthrough in the treatment of onychomycosis?
• Is TB-403 usefull in the Treatment of Hemangiomas?
• Is the efficacy of a molecule with two antibody functions <, >, or = to administering two antibody therapies separately?
• Is there a Dr. in The House,ER,Soaps,Ben Casey, Dr. Kildare,Chicago Hope, etc or is it an illusion?
• Is this Financial Life Preserver to Primary Care Physicians going to be Enough?
• Is this the next design for your presbyopic correction of contact lens, laser vision, or cataract procedure?
• John McCain Bashes Pharma
• Joint collaboration between Galapagos NV and Eli Lilly and Company (NYSE:LLY)- Is this going to work ?
• Joint collaboration between GSK and Santaris Pharma - a road for new therapies
• Judge Saris on Fictitious AWPs
• KX2-391 (Kinex Pharmaceuticals) too early to call.
• Lacosamide Should Solidify UCB as CNS Drug Leader
• Leading Boston Area Hospitals Force Their Physicians to Go Electronic
• Legalised tougher action for failing nursing homes: a move towards bipartisan legislation
• Less Could be More...a Sign of Hope
• lessons from the British National Health Service
• Let this drug die in peace
• Lexapro(R) phase III study positive results to treat depression- a joint collaboration from Forest Laboratories and Lundbeck
• Lexapro® can be a household name for curing children's depression.
• Likely a useful addition
• Likely to be approved but with restrictions in use
• limited market for tzds
• Liraglutide benefis in obesity not as greater as authors claim when compared to Orlistat
• Long way before it can replace conventional opiate
• Lots of Pomp and Circumstance but Can Revance Deliver?
• Love'em Hate'em but Use Them
• Lu AA21004 is making progress to enter the clinical III trial - collaboration from Lundbeck and Takeda
• lubrication will be the ultimate answer
• LymphoStat in SLE
• M Vax for metastatic melanoma: rational study design and adequate numbers to test efficacy
• Makes it easier to use, but not more affordable
• Market continues to shift for health coverage
• Massive statin market misfits waiting for safe alternative!
• May give Januvia a run for its money
• McKesson Buyout Rumors
• me too drug!
• Medicare and Medicaid on the Way to Bankrupting the Country
• Medicine of the year SEROQUEL (by MedAdNews) Ready for SEROQUIL XR as the new Medicine of the Year.
• Medicis and Revance topical botox promising.
• Medtronic loses litigation to DePuy over polyaxial Vertex screws, what is the significance?
• MEM 3454 is showing cognitive benefits for Alzheimer's Disease: Phase 2a outcome
• meningococcal meningitis, Pediatric Labeling Impact
• Menveo: Good News for Novartis, but Perhaps Better News for sanofi
• Merck KGaA and Idera TLR9 deal for cancer - too early to know if it is important
• Merck’s Agreement With Addex To Develop ADX63365: Eli Lilly May Have Competition In Groundbreaking Glutamate-Based Treatment of Schizophrenia.
• Meridian's Point-of-Care Testing Should Find a Home in Pediatric Offices
• Mircera will sell well in CKD and well in Europe
• Mixing/Matching Multifocal and Accommodating IOLs
• More bad news for Epo products, J & J & Genentech?
• More Glucose Sensor Progress
• More icing
• More icing on the cake
• More trouble for Amgen & J &J. FDA tightening control of Epo use
• MP470 In Vitro or In Vivo, no human trials yet......
• MRSA Investment Opportunities
• MRSA--Widespread, but not necesarily devastating
• mTCR: a biomed black swan?
• New Anticoagulants: pipelines providing multiple candidates to take over the market.
• New Broad Spectrum Antibiotic - 2 New Phase 2 Studies
• New Glaucoma Product Should Simplify Patient Compliance and Increase Allergan's Share of Glaucoma Market
• New insight into asthma?
• New Treatment for Chronic Hepatitis C Infection
• New Trial to Treat Metastatic Uveal Melanoma
• NF KappaB decoy technology innovative in inflammatory skin diseases
• NF-kB decoy, licensed for more clinical trial by Dr Xin Mao
• Nice concept but what is the cost?
• Nice result but will hard end-points change
• non calcium phosphate binders
• Not a concern for internist
• Not a major concern in enuressi treatment
• Not Another mGluR Drug: The Competition Is On.
• Not Surprised
• Nothing new, but important
• Novartis " a rolling stone gathers ........."
• Nursing Homes to Receive More Oversight
• Nycomed and Bradley Pharmaceuticals Making Dermatology Better.
• Nycomed's Bradley acquisition could fit expansion into veterinary dermatologics
• Oh My Aching Knees...Chondrogen and the future of non-operative treatment of knee arthritis
• Old news is Never New News
• One of the most important steps but.......
• oral route of administration may impact comliance
• Organon to no longer be manufacturer of Zemuron and Norcuron ?
• Orphan status does not mean efficacy
• Osteoporosis Treatment: What's next?
• ouch! should not cut it.
• PARP inhibitor to be tested against triple negative breast cancer in randomized Phase II trial
• Part D and Generic Substitution
• PBI-1402 How Exciting for Anephric Rats.....
• PBMs: Little Impact if Benchmark Changes to AMP
• PEG-INTRON + ribavirin approved in EU for retreatment of hepatitis C
• Perhaps the Most Important Reason for Exubera Failure is that No One Wanted to Pay for it
• Perifosine (AEterna Zentaris) Trial in Lung Cancer. What Will It Answer???
• Pfizer's enhancing biologic portfolio through the acquisition of CovX
• Pfizer's formal move to acquire Coley (a specialized biopharmaceutical company)
• Pfizer's Loss is Wyeth, Novartis and Bayer's Gain
• Pharmaceutical greed and the fleecing of medicare
• Pharmacy Profits & PBM Contracts
• Pharmexa's HeptoVax? Too Tough to Call
• Phase III Ascentar (NOVC) Study Halted - Ineffective Drug or Faulty Trial Design?
• Phase III Trials for Clonicel for ADHD in the U.S :a joint venture from Sciele Pharma, Inc. and Addrenex Pharmaceuticals
• Physicians Escape Electronic Records Mandate--For Now...
• Physicians Face a 10% Medicare Pay Cut Unless they Adopt Electronic Records
• Picoplatin- May be a winner, but let's await the trial results.
• Platelet inhibition is a surrogate marker of unknown utlity
• POLITICAL POSTURING WITH LITTLE THOUGHT FOR RESULTS.
• Preventive care is a big part of the answer
• PRISTIQ (Wyeth: WYE) Will Follow in the Footsteps of LEXAPRO (Forest: FRX)
• Pristiq and Major Depression
• PRISTIQ--the new desipramine?
• Procrit, Epogen, Aranesp and other "new" ESAs. Hand me another coffin nail.....
• Promising Humira, surprinsing ABT-874
• R84, an anti-VEGF antibody
• Ranbaxy Receives Tentative Approval For Valsartan Tablets from the FDA
• Ranexa - CV Therapeutics, Inc. (Nasdaq: CVTX) - MERLIN TIMI-36 BNP Analysis Broadens Indications
• Ranexa results encouraging
• Rapid testing welcome
• Reduction in Medicare Payments to Docs?? Don't bet on it.
• Reduction of fracture is what counts!
• Reloxin Gives Allergan's Botox A Run for the Money!
• Reloxin submission to the FDA
• Reloxin Will Have a Huge Impact on Younger Women Entering Cosmetic Dermatology
• Remicade: Interrupting the Natural Progression of Inflammatory Bowel Disease
• Restricted use of Avandia for U.S veterans - safety issue
• Results of phase 1 trial, on treatment of parkinson's disease, presented @ scientific forum
• Revised label for Avandia by GlaxoSmithKline
• Revlimid benefits seem overstated in non-5Q minus MDS
• Revlimid in non 5Q- MDS. It's time is coming!!!!
• Revlimid plus Decadron beats Decadron alone in Multiple Myeloma. Go figure??
• Rimonabant for Weight Control: No Pain No Gain (or Loss)
• Rimonabant will be prescribed less now that severe psychiatric disorders have been identified as a side effect
• Risk benefit ratio for prescribing can be more complex in younger people
• Risk in using Avandia - increase risk of brittle bone disease
• Risk of Psychiatric disorder from weight-Loss drug Rimonabant intake
• Risk Versus Benefit
• Risky health cover costs - a change in plan ?
• Roche likely to go back to the drawing board
• S-1. An effective adjuvant treatment.... In the US????
• Schizophrenia treatment options target glutamate
• Score 1 for Sutent (Maybe)
• Screening Cat Scans Reduce Lung Cancer Mortality???
• Serotonin and satiety is very interesting
• SF1126- Efficacy?? Lets see how more rodents do......
• Should be a good generic choice
• Should We Treat Colds In Children?
• Side effect still may hamoer drug
• Significant finding
• Significant improvement in a very difficult to treat problem
• Slit may be wave of the future but not yet in the US
• So much for Lilly's arzoxifene in breast cancer therapy, but prevention & osteoporosis???
• So what is new?
• Something for constipation
• Start of phase II study of Immunodrug™ CYT003-QbG10 for the allergic disease treatment by Cytos Biotechnology
• Statistical significance may not mean much in real life
• Stifel and Allergan collaboration very positive
• Suggested meaning of MT103 (MEDI-538)
• Surprise! Mandatory Electronic Prescribing Hiding in the Medicare Modernization Package
• Survey Reveals Many Americans Admit to Having Difficulty Driving At Night, But Few Seek Help From Eye Care Professionals
• Survival benefit important for reimbursement in Europe.
• sutent will stay
• Sutent's cardiac toxicity is real and will decrease its use
• Swedish Medical Products Agency approves Phase Ib clinical trial with NsG0202 for the treatment of Alzheimer's disease
• SYNERGISM: Lilly and MacroGenics Announce Licensing and Collaboration Agreement
• Synvisc-One Could Be a Blockbuster: Bet on it!
• Sysmex has potential to expand current penetration and open new market
• Taisho/Pfizer’s TS-032 for Schizophrenia: A New Player in mGluR Field
• Takeda & Lundbeck Expect a Happy Marriage and Drug Approval
• Tanespimycin Is likely to be a biggy in Multiple Myeloma (MM)
• Tanespimycin: a heat shock protein inhibitor (HSP90) inhibitor in multiple myeloma (MM) could be a "shock?"
• Tanespimycin: A potential player in treatment of MM and other hematological malignancies
• Tasigna (nilotinib) Innovative as well as well positioned for Novartis in cheronic myeloid leukemia..
• Telcyta Not Dead..... Yet
• Telomerase vaccine: Promising , but main role is in minimal residual disease
• Temodar produces modest but definite long term survival when added to radiation in GBM
• Temodar, Schering-Plough Corp., improves survival in Glioblastoma patients....
• That's One Small Step for the Feds...One Giant Leap for Electronic Records?
• The AMP Lawsuit Gambit
• The approval of topotecan
• The bar is raised for starting antibiotics or steroids
• The Case for Remicade
• The effectiveness of Apollo’s Oradel technology is confirmed by US researchers
• The emFasis on the wrong syLabble....
• The European Veramyst - but ocular symptom control raises questions
• The Feds are mandating EMRs
• The future impact of this approval is unclear
• The impact in disease prevention efforts is how you identify root problems
• The impact of HSD1 inhibitor on decreasing diabetes, hypertension, obesity, heart disease and their complications
• The Law of Unintended Consequences strikes again
• The Prevelence of Hearing Impairment in the Middle East
• The real danger is alarming the public !
• The Start of an Exciting, But Long Road
• the truth about avandia and osteoporosis
• The Vidaza survival benefit news is a positive for MGI Pharma's Dacogen
• Theword of mouth
• thiazolidinedione demise will support Januvia use
• This may not be exactly what the doctor ordered
• This trial confirms zevalin's effectiveness - limited prescribing remains a block to timely use.
• Time to talk to the FDA
• TLR therapeutics: Immunomodulators with role in combination therapy and minimal rtesidual disease
• TLR9 Agonists have a big hurdle to climb
• TLR9 Agonists Intriguing If Cytokines Treat Cancer
• To Err is Human, To Report...Divine!
• Too little, too late
• Topical "Botox"--Sounds Like a Winner
• Topical Valproic acid has efficacy but the main treatment is still surgical
• Torisel (Wyeth). Innovative? YES!!!
• Torisel for renal cell cancer: efficacy with favorable safety profile
• tough to know how meaningful without more detail
• TRAVEL FOR CARE NOT A REGIONAL-ONLY MARKET
• Treating depression should be part of treating all chronic illnesses
• Treatment of Acute Maxillary Sinusitis - Antibiotics and Topical Nasal Steroid
• Trubion's TRU-015 in RA
• Two for the price of one
• U.S. Ophthalmologists Still Waiting for Prostaglandin/Timolol Combo
• Undue Pessimism
• Uniformity of any Prescription supplier can be important if not perhaps critical.
• Universal Health Coverage by Federal Government- A Big Mistake
• Unwilling to face reality, families will combine potentially toxic agents to treat cancer.
• Use of Antagonist Targeted to vWF in Treatment of Thrombosis
• Use of Intranasal Desmopressin Already on the Decline
• Use of Pegylated Interferom and Ribavirin as Retreatment - No Advance
• Ustekinumab
• Ustekinumab for Autoimmune Diseases
• Ustekinumab-new drug that gets to the core of psoriasis
• Uveal Melanoma: Can Marqibo Hit a Home Run?
• UVIDEM Cnacer vaccine for melanoma: early results promising with durable responses.
• UVIDEM dendritic cell vaccine release Phase II results in advanced melanoma
• Valsartan is not a new drug
• VAP reporting - the wrong quality measure to report
• Varian's New Rapid Arc VMAT(Volumetric Modulated Arc Therapy) Technology
• Velcade First Line Therapy: It should be approved, BUT will it live up to Millennium's expectations?
• very bad news
• Very Good News For HIV Infected Individuals. Sandro Vento, MD. Azienda Ospedaliera di Cosenza, Italy
• Very Interesting Diabetes Data From an Unlikely Source
• Viva, Vivaglobin??
• Vx-001 in TERT-positive non-small-cell lung cancer. Chance of efficacy?
• Watch out Tomo....here comes some competition
• We are about to go live with EMR
• We don't treat colds, we treat children
• We need better antibiotics
• Wellcare - How bad Might it Be?
• Wet pajamas must be back in style???
• What Impact Will the FDA’s Rejection of GlaxoSmithKline’s Gepirone ER Have for Other Experimental Serotonin 5-HT1a Partial Agonists in Depression?
• What is the value of HPV vaccines?
• WHO WON?: –> The Injured, Merck or The lawyers?
• why are drugs exempted
• Why the radioimmunoconjugates won'yt catch on
• Wide prospect for New Allergic Rhinitis Treatment Avamys: positive opinion from Medicines Agency (EMEA
• Would you be excited if I told you I had a new model car?
• Wrong test results = wrong treatment recommendations
• WYETH's PRISTIQ MAY WELL BE A BLOCKBUSTER!!!!!!!!
• XL184 (Exelixis) may have an agent that can be given with other targeting agents (EGFR) in Lung Cancer.
• Yeah, injections hurt....
• You can never get something for nothing!
• Zevalin (Bayer) a great agent in lymphomas that will NOT be used because......
• Zevalin for Follicular Lymphoma: Very effective but not very practical to use